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Abstract
Background: The role of the high affinity IgE receptor, FceRI, in IgE-mediated immune responses of the gastrointestinal (GI)
mucosa is poorly understood. Currently, a detailed characterization of FceRI expression throughout the human gut is
lacking. The aim of this study was to define the expression pattern of FceRI in the GI tract.
Methods/Principal Findings: We compared FceRI expression in children with gastritis/esophagitis (n=10), celiac disease
(n=10), inflammatory bowel disease (IBD) (n=9), and normal mucosa (n=5). The a–subunit of FceRI (FceRIa), detected by
immunohistochemistry, was found on cells infiltrating the mucosa of the esophagus, the stomach, and the duodenum, but
was rarely detected in more distal sections of the GI tract. Accordingly, quantitative RT-PCR analysis on esophagus, stomach,
duodenum, colon, and rectum biopsies revealed that FceRIa and -b expression levels decreased towards the distal intestine.
mRNA transcripts of the common Fc-receptor-c chain were present in the entire GI mucosa. Double-immunofluorescence
staining of esophageal specimens confirmed that FceRIa was expressed on intraepithelial mast cells and Langerhans cells.
The mRNA expression levels of the a, b, and c subunits of FceRI did not correlate with total serum IgE but were associated
with mucosal inflammation.
Conclusion/Significance: Our data define the upper GI tract as the main site for IgE-mediated immune activation via FceRI.
Tissue mRNA levels of FceRIa are regulated by inflammatory conditions rather than serum IgE, indicating that FceRI might
also play a role in pathologies other than allergy.
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Introduction
The gastrointestinal (GI) mucosa is a large interface area for
pathogens and environmental antigens and, therefore, is under
constant surveillance of the immune system. Immunoglobulin (Ig)
receptors are gatekeepers of host defense at mucosal surfaces; they
shuttle Ig-antigen complexes across the healthy epithelium and
activate protective immune responses. Misguided immune re-
sponses, however, can lead to inflammation of the gut or other
allergic reactions towards harmless allergens. IgE and its cellular
receptors are key players in allergic reactions and parasite defense.
Humans express three IgE-receptors, the high affinity IgE-
receptor, FceRI, and two low-affinity IgE receptors, FceRII (or
CD23), and e-binding protein eBP (or galectin 3) [1]. In the
human GI mucosa, the expression of the low affinity IgE receptors
is well documented; CD23 is expressed on intestinal epithelial cells
and functions as an antigen-sampling protein for IgE-antigen
complexes, implying that CD23 plays a role in food allergy
[2,3,4,5,6,7]. Galectin 3 has been shown to be downregulated
during intestinal inflammation and is associated with colon cancer
progression [8,9,10,11]. There is little data, however, on the
expression profile of the high affinity receptor FceRI in the
gastrointestinal mucosa.
FceRI is a multimeric receptor of the immunoglobulin receptor
superfamily and binds the Fc-part of IgE with its immunoglobulin
domain-containing a-chain. Allergen-mediated crosslinking of
IgE-FceRI complexes on the surface of blood and tissue cells
then triggers the allergic cascade via the receptor’s signaling
subunits, FceRIb and FceRIc [12]. Human FceRI is expressed in
a tretrameric form (FceRIabc2) on the surface of mast cells and
basophils, and in a trimeric form (FceRIac2) on eosinophils,
macrophages, and dendritic cells (DCs) [1]. In peripheral blood,
the majority of FceRI-expressing cells carry IgE [13,14]. Since
binding of IgE to FceRIa stabilizes the IgE-receptor complex, cell
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e42066surface expression of FceRI on peripheral blood cells has been
shown to tightly correlate with serum IgE levels as well as cell-
bound IgE [15,16,17].
In the GI tract, FceRI-expressing DCs of the Langerhans cell
type have been described in the oral mucosa [18] and in the
esophageal epithelium of children with gastroesophageal reflux
and Eosinophilic Esophagitis (EoE), an allergic condition of the
upper GI tract [19]. FceRI is the only IgE receptor that is
expressed in the esophagus [19]. Untersmayr et al. detected
FceRI-positive epithelial cells in the terminal ileum and the colon
of colon cancer patients and patients with inflammatory conditions
of the gut [20]. Previously, IgE-loaded mast cells have been
described in the intestinal mucosa of food allergic- as well as
healthy individuals [21,22].
A detailed analysis of mucosal FceRI expression throughout the
GI tract is currently not available. The aim of the present study,
therefore, was to characterize the expression pattern of FceRI
throughout the GI tract and to investigate the impact of serum IgE
levels and mucosal inflammation on FceRI expression levels.
Results
Study Population
We investigated mucosal specimens from a total of 34 pediatric
patients (15 girls, 19 boys, median age at time of endoscopy 12.4
years). Patients had a diagnosis of gastritis/esophagitis (n=10),
celiac disease (n=10), or inflammatory bowel disease (IBD) (n=9).
Biopsies of 5 patients did not show any mucosal pathology and
served as normal controls. Total serum IgE was measured at the
time of endoscopy. Fifteen patients had elevated serum IgE levels
(gastritis/reflux n=5, celiac disease n=5, IBD n=4, normal
n=1). In 19 patients, IgE levels were within the normal range.
Patients’ characteristics are summarized in Table 1. Children were
not routinely tested for the presence of intestinal parasites or
helminths, but the expected prevalence for such infections is
negligible in a Central European country.
Histological Detection of FceRI in the GI Mucosa
We conducted immunohistochemistry staining of snap-frozen
mucosal biopsies from all sections of the GI tract accessible by
endoscopy. FceRIa was frequently found on cells infiltrating the
mucosa of the upper GI tract (esophagus, Figure 1A and F,
stomach Figure 1B and G, and duodenum, Figure 1C and H).
Specimens from the lower GI tract (terminal ileum, colon, and
rectum) showed only scattered FceRI positive cells (Figure 1D
and I). We recently identified Langerhans cells and mast cells as
the main bearers of FceRI in the esophageal epithelium by
immunohistochemistry double-staining [19]. Here, double-im-
munofluorescence staining of snap-frozen esophageal specimens
confirmed that FceRI was expressed on c-kit-positive intrae-
pithelial mast cells (Figure 2) and CD1a-positive Langerhans cells
(Figure 3).
FceRIa, ß, and c are Robustly Expressed in the Upper
Gastrointestinal Tract
Because immunohistochemistry does not allow for quantifica-
tion of protein expression levels and might not be sensitive enough
to detect low-level expression of FceRI subunits, we employed
quantitative RT-PCR to screen gastrointestinal biopsies for
FceRIa-, -ß-, and -c-mRNA. We detected FceRIa mRNA in all
esophageal biopsies (29/29), in 5/34 gastric samples, 8/33
duodenum samples, 1/12 terminal ileum samples, 2/13 colon
samples, and 1/13 rectum samples (Figure 4A, left panel). FceRIb
transcripts were found in 18/29 esophageal samples, 9/34
stomach samples, 6/33 duodenum samples, 3/12 terminal ileum
samples, 2/13 colon samples, and 1/13 rectum samples, Figure 4A,
middle panel). In line with its function as a common signaling
chain for several Fc receptors [23], Fc-receptor-c mRNA was
present in most specimens from all sections of the gut (right panel).
FceRIa mRNA levels were highest in the esophagus and decreased
along the GI tract (Figure 4B, left panel). FceRIb mRNA-
expression peaked in the gastric mucosa (middle panel). Esoph-
ageal specimens were low in FceRIc transcripts compared to the
stomach, terminal ileum, colon, and rectum (right panel, Mann-
Whitney-U test). This data demonstrate that, as measured at the
mRNA level, the FceRIa and b subunits are robustly expressed in
the proximal parts of the GI tract and their expression levels
decrease towards the distal intestine, while the common Fc-
receptor-c chain is expressed throughout the entire GI mucosa.
Tissue mRNA Levels of FceRIa do not Correlate with
Serum IgE Levels
IgE-binding to FceRIa stabilizes the receptor complex at the
cell surface [15]. It has also been suggested that IgE-binding
promotes FceRIa transcription [24]. Therefore, we investigated
the correlation of serum IgE levels with tissue mRNA levels of the
three FceRI-subunits. In specimens from the esophagus, the
stomach and the duodenum with detectable FceRIa-, b-, or c-
mRNA expression, no correlations between serum IgE and any of
the receptor subunits were found (Figure 5A, Spearman rank
correlation). Additionally, a comparison of tissue mRNA levels of
FceRIa and b between children with elevated IgE and normal IgE
did not show any significant differences in the upper GI tract
(Figure 5B, left and middle panel). The highest number of FceRIa
mRNA transcripts was observed in the esophageal mucosa of
patients with elevated IgE though (Figure 5B, left panel). FceRIc
transcripts did not significantly differ between elevated- and





(Range) z-units Median (Range) Elevated IgE (n)
Total 34 15/19 12.37 (2.72–18.03) 21.90 (2.0–1,510) 0.52 (21.74–3.81) 15
Gastritis/Esophagitis 10 3/7 12.93 (2.72–16.86) 27.55 (2.8–300) 0.55 (21.74–2.38) 5
Celiac’s Disease 10 7/3 8.69 (3.18–17.44) 22.35 (0–630) 0.66 (21.57–3.81) 5
IBD 9 2/7 15.30 (6.15–18.03) 7.5 (0–1,510) 20.86 (21.68–3.73) 4
Normal Mucosa 5 3/2 11.93 (3.36–12.49) 33.40 (9.4–347) 0.52 (20.62–2.54) 1
IBD: inflammatory bowel disease.
doi:10.1371/journal.pone.0042066.t001
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Mann-Whitney-U test, respectively). The low frequency of
FceRIa- and b-mRNA positive specimens did not allow for
comparative analysis in the large intestine.
Our experiments permit us to conclude that our findings
regarding the correlation of serum IgE levels and FceRI expression
in peripheral blood [13] cannot be extended to the GI mucosa.
FceRI mRNA Expression Levels are Modulated by
Inflammation of the GI Tract
We have previously shown that FceRI-bearing immune cells
infiltrate the esophageal mucosa of children with reflux esophagitis
and EoE, two inflammatory conditions of the esophagus [19]. We,
therefore, hypothesized that the mucosa of patients with in-
flammatory conditions of the gut should express high levels of
FceRI transcripts due to the influx of inflammatory immune cells.
In support of this hypothesis, we found that some gastritis/
esophagitis patients in our study showed higher FceRIa mRNA
levels in the esophagus than celiac disease- and IBD-patients or
normal controls (Figure 6A). We note that the specimens that
contained FceRIa mRNA in the terminal ileum, the colon, and
the rectum were obtained from two IBD patients, while one colon
biopsy from a normal control patient was also positive for FceRIa
mRNA. In the gastric mucosa, FceRIb mRNA levels appeared to
Figure 1. Immunohistochemistry with FceRIa specific antibody (mAb 15-1) on snap-frozen intestinal specimens from (A) the
esophagus, (B) the stomach, (C) the duodenum, and (D) the colon. FceRIa-positive cells (red) are frequently found in the esophagus, the
stomach, and the duodenum (black arrows). (E) shows isotype control with mouse IgG1. Goblet cells in the duodenum and the colon revealed non-
specific binding of antibodies. Original magnification x20. Bottom row (F-J) shows details from A-E. Representative specimens from n=10.
doi:10.1371/journal.pone.0042066.g001
Figure 2. c-kit positive mast cells in the esophagus epithelium express FceRIa. (A) FceRIa is visualized with mAb Cra1 (green, first panel).
Mast cells are shown with c-kit as a marker (red, second panel). Cell nuclei are visualized with DAPI staining (blue). (B) shows higher magnifications
from (A). FceRIa is expressed on esophageal mast cells (B, white arrows). Representative specimens from n=3.
doi:10.1371/journal.pone.0042066.g002
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These differences, however, were not statistically significant
(measured using a Kruskal-Wallis test). A statistically significant
difference between patient subgroups was found for the FceRIc
expression levels in gastric specimens (Figure 6C, p=0.031,
Kruskal-Wallis test). Group-by-group comparison did not reveal
statistically significant differences between the respective patient
subgroups though (Mann-Whitney-U test with Bonferroni-Holm
correction for multiple testing). In summary, our data suggest that
inflammatory infiltration of the GI mucosa may be associated with
an increase in FceRI tissue mRNA expression, although the small
patient cohort did not permit statistically significant results.
Discussion
We show here that the high affinity IgE receptor, FceRI, is
highly expressed on cells infiltrating the mucosa of the esophagus,
the stomach, and the duodenum, and shows a low level of
expression in more distal parts of the GI tract. Accordingly, tissue
mRNA of all three FceRI subunits was detected in the intestinal
mucosa. FceRIa-, b-, and c-mRNA levels did not correlate with
total serum IgE, but were modulated by gastrointestinal in-
flammation.
FceRIa mRNA was most abundant in the esophageal mucosa
and could be detected in every patient. FceRIb mRNA levels, on
the other hand, were rather low in the esophagus and peaked in
the gastric mucosa. This could reflect the predominance of cells
expressing the trimeric receptor isoform, such as dendritic cells
and eosinophils, in the esophagus. In the stomach, cells bearing the
tetrameric FceRIabc2, such as mast cells and basophils, could be
the main FceRI-expressing population. This interpretation is
supported by previous studies showing that the gastric mucosa is
particularly rich in mast cells [25,26,27], whereas in the esophagus
eosinophils and dendritic cells are the major FceRI-positive
populations [19]. The common Fc-c-chain mRNA was abun-
dantly found in almost all biopsies. The increasing levels of the
Fcc-chain along the GI system most likely reflect the physiologic
increase in Fc-receptor-bearing mucosal immune cells even in
healthy subjects [28,29].
The binding of IgE, the natural ligand to FceRI, increases
FceRI expression on peripheral blood cells and Langerhans cells
[13,30,31] by stabilizing the receptor on the cell surface [15]. It
has been suggested that IgE also upregulates FceRIa transcription,
although this hypothesis has been disputed [24,32]. We did not
find any significant correlation between mucosal FceRIa-, -b-, or -
c-mRNA expression levels and serum IgE in any part of the GI
tract. Our data thus support earlier observations that FceRI
expression is likely regulated on the protein rather than the mRNA
level [32].
Total IgE values in mixed-age pediatric populations are not
directly comparable due to differing age-related normal ranges. To
overcome this problem, absolute IgE levels are commonly
converted into age-normalized z-values as published by Kjellman
et al. [33]. We did not detect a significant correlation when we
used z-units instead of absolute IgE values either (data not shown).
Nonetheless, it is possible that the mucosal immune system is more
autonomous than previously assumed. Vicario et al. recently
discovered local isotype class-switching to IgE and IgE production
in the esophageal mucosa of EoE patients, regardless of their
atopic status [34]. Local IgE production might also boost mucosal
FceRI-expression, independent of systemic serum IgE levels.
We observed that mucosal inflammation was associated with
FceRIa mRNA levels, based on our finding that patients with
a histopathological diagnosis of esophagitis displayed the highest
FceRIa mRNA expression. The highest copy numbers of
Figure 3. CD1a-positive Langerhans cells in the esophagus epithelium express FceRIa. FceRIa is visualized with mAb Cra1 (green, first
panel). Dendritic cells are shown with the Langerhans cell marker CD1a (red, second panel). Cell nuclei are visualized with DAPI staining (blue).
Representative specimens from n=3.
doi:10.1371/journal.pone.0042066.g003
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patients. According to routine pathology records, these two
patients also had intraepithelial inflammatory infiltrates in the
esophagus. Therefore, high FceRIa mRNA expression could be
a surrogate for invading FceRIa-positive inflammatory cells.
Further supporting this argument, previous studies identified
intraepithelial Langerhans cells and mast cells in the inflamed
esophageal mucosa of children with EoE and reflux esophagitis as
the main cellular sources of FceRI [19,35]. Other studies
described the infiltration of IgE-loaded mast cells in the duodenal
mucosa of patients with food-related diarrhea [21]. In line with
these previous findings, we also identified intraepithelial mucosal
mast cells and Langerhans cells as the FceRI-expressing cells. With
respect to the distal sections of the intestine, Untersmayr et al.
recently identified epithelial FceRIa expression in Paneth cells in
small intestinal crypts and colon epithelium in colon cancer
patients, and in patients with various gastrointestinal inflammatory
conditions. Samples from healthy controls were negative for the
receptor in this study. The authors, therefore, proposed a role for
mucosal FceRI expression in gastrointestinal pathology [20]. Our
data support Untersmayr’s data as two out of nine IBD patients
were positive for mucosal FceRIa mRNA in the terminal ileum
and the large intestine.
The role ofthe low affinity IgEreceptor, CD23,intransepithelial
transfer of IgE-allergen complexes is well established [5]. FceRI, in
contrast, does not seem to be involved in antigen-shuttling, as it is
localizedtoinfiltratingcellsratherthanepithelialcells.Itistempting
to speculate that FceRI may function as an antigen uptake-receptor
on mucosal DCs with the capacity to sample allergen from the
gastrointestinal lumen via FceRI-bound specific IgE, as has been
shown in mouse models [36,37,38].
In summary, we show here that FceRI is robustly expressed in
the upper GI mucosa of pediatric patients at steady state.
Inflammatory conditions, independent of the underlying pathol-
ogy, lead to increased FceRI tissue mRNA expression. In
conclusion, our data define the upper GI tract as the main site
for IgE-mediated immune activation via FceRI. Once the immune
homeostasis is disturbed by an inflammatory condition such as
IBD, the lower GI tract becomes susceptible to IgE-mediated
immune reactions as well. The fact that we see tissue FceRIa
mRNA regulation by inflammatory conditions independent of
IgE-mediated disorders indicates that this receptor might also play
a role in pathologies other than allergies.
Materials and Methods
Ethics Statement
The study protocol was approved by the Ethic’s Committee of
the Medical University of Vienna. Patients or their legal guardians
provided written informed consent.
Figure 4. Quantitative RT-PCR for the three subunits of the high affinity IgE-receptor was performed on intestinal biopsies from
pediatric patients. (A) FceRIa mRNA transcripts were found in all esophageal biopsies and with varying frequency in more distal biopsies (left
panel). Similarly, the highest frequency of FceRIb mRNA-positive specimens was found in the esophagus (middle panel). The common Fc-c chain was
detected in the majority of specimens from the entire GI tract (right panel). Black stacked-bars represent target-positive specimens, and white
stacked-bars represent target-negative specimens. (B) The highest levels of FceRIa mRNA transcripts were found in the esophageal mucosa (left
panel), while FceRIb mRNA expression peaked in the gastric mucosa (middle panel). Esophageal specimens revealed the lowest FceRIc mRNA
expression compared to the stomach, terminal ileum, colon, and rectum (right panel). * p,0.05, Mann-Whitney-U test.
doi:10.1371/journal.pone.0042066.g004
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Children between 2 and 18 years of age who underwent elective
diagnostic endoscopy of the upper and/or lower GI tract at the
Department of Paediatrics and Adolescent Medicine, Medical
University of Vienna were randomly invited to participate.
Subjects with increased risk of bleeding or perforation and
patients scheduled for endoscopic interventions or undergoing
non-elective endoscopy were excluded. Endoscopic biopsies from
the esophagus, the stomach, the duodenal bulb, the terminal
ileum, the ascending colon, and the rectum were either fixed in
OCT Tissue Tek (Sakura Finetek, Staufen, Germany) and stored
at 280uC until further processing for RT-PCR or snap-frozen for
immunohistochemistry analysis. Tissue specimens were obtained
from sites free of macroscopic mucosal pathology.
Immunohistochemistry
FceRIa in frozen sections of gastrointestinal specimens was
detected with mAb 15.1 [31]. Sections were acetone-fixed,
rehydrated and blocked in 2% (w/v) BSA/phosphate buffered
saline (PBS). Endogenous peroxidases were quenched with 0.3%
hydrogen peroxide/PBS for 15 minutes. Sections were exposed to
blocking solution containing 2% horse serum for 20 minutes and
incubated with mAb 15.1 or concentration-matched mouse IgG1
isotype control overnight at 4uC. Bound antibody was detected
with VectastainH ABC peroxidase system (Vector-labs, Peterbor-
ough, UK) according to the manufacturere’s protocol and
visualized with AEC reagent (3-amino-9-ethylcarbazole; Dako,
Carpinteria, CA, USA). Sections were counterstained with
Papanicolaous Harris 1a stain (Merck, Darmstadt, Germany).
Figure 5. Correlation of FceRI mRNA levels (DDCt) and serum IgE levels (kU/l). (A) Scatter plots of serum IgE levels versus FceRIa- (left
column), FceRIb- (middle column), and FceRIc-mRNA transcripts (right column) in the esophagus (top row), the stomach (middle row), and the
duodenum (bottom row). rho, Spearman rank correlation coefficient. (B) Comparison of mRNA levels of the three receptor subunits between patients
with elevated IgE (high IgE, filled triangles) and patients with normal IgE (open triangles) did not reveal any significant difference (Mann-Whitney-U
test).
doi:10.1371/journal.pone.0042066.g005
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Double immunofluorescence staining for FceRIa and the mast
cell marker c-kit or the Langerhans cell marker CD1a were
performed on frozen esophagus specimens. Sections were acetone-
fixed, incubated with 1 mg/ml sodium borohdyride (ICN
Chemicals, Aurora, OH), and blocked with 5% v/v normal
donkey serum (Jackson ImmunoResearch Lab Inc., West Grove,
PA, USA). Sections were then exposed to mouse anti-FceRIa (Cra
1, clone AER-37, 1:100 dilution, eBioscience, San Diego, CA,
USA) and goat anti-CD1a (clone N-19, 1:200 dilution, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) or rabbit anti-c-kit
(A4502, 1:250 dilution, Dako) overnight. CY5-conjugated donkey
anti-mouse-, Dylight 549 donkey anti-goat-, and Dy549 donkey
anti-rabbit-antibodies (Jackson ImmunoResearch Lab Inc., 1:200
dilution) were used as secondary antibodies. Secondary antibody
controls were performed in parallel with each experiment. After
they were washed, the sections were mounted with Prolong Gold
anti-fade mounting media containing DAPI (Invitrogen, Grand
Island, NY, USA). FceRIa/CD1a double-staining was investigated
on a Zeiss AxioImager M1 wide-field fluorescent microscope with
a 20x/0.8 N.A. plan-apochromat objective lens and the AxioVi-
sion software. FceRIa/c-kit double staining was investigated on
a Zeiss LSM510 Meta confocal system and Zeiss LSM510 image
acquisition software. The images were taken with a 20x/0.8 plan-
apochromat objective and a 40x/1.3 oil plan-apochromat
objective.
Real-time RT-PCR
Total mRNA was isolated from mucosal specimens using the
GenElute
TM Total RNA MiniPrep Kit (Sigma-Aldrich, St. Louis,
MO, USA) and subjected to reverse transcription with the
iScript
TM cDNA synthesis kit (Bio-Rad, Hercules, CA, USA)
following the manufacturer’s instructions. Quantification of
mRNA was performed using the iQ SYBR Green Supermix
(Bio-Rad) on a CFX96 Real time System (Bio-Rad). The thermal
profile of the PCR reaction was: initial denaturation at 95uC for 3
minutes, followed by 30 cycles of denaturation at 95uC for 10
seconds and annealing/elongation at 63uC for 30 seconds, and
a final melting curve. The following primers were used to amplify
cDNA: FceRI a: forward: 59GAA ATG TGA CCT GCT GCT
GA39, reverse: 59TGT GGC AGC TGG ACT ATG AG39; beta-
Actin: forward: 59CTC TTC CAG CCT TCC TTC CT39,
reverse: 59AGC ACT GTG TTG GCG TAC AG39. Primer sets
for FceRIb and -c subunits and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) were purchased from Qiagen (Hilden,
Germany). Relative expression of FceRIa,-b and -c was calculated
according to the Pfaffl method [39] as follows: DDCT=DCt(sam-
ple)- DCt(reference), where DCt(sample) is the Ct value of the gene
Figure 6. FceRI mRNA expression levels in the upper gastrointestinal tract under inflammatory conditions. (A) FceRIa-, (B) FceRIb-, and
(C) FceRIc-mRNA expression levels in specimens from children with gastritis/esophagitis (open squares), celiac disease (open triangles), inflammatory
bowel disease (IBD) (open diamonds), and normal mucosa (open circles). * p,0.05, Kruskal-Wallis test.
doi:10.1371/journal.pone.0042066.g006
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GAPDH and beta-Actin and DCt(reference) is the sample with the
lowest DCt value. cDNA from palatine tonsils was used as positive
control and included in each experiment as inter-run calibrator.
Total Serum IgE Measurement
Serum samples for IgE measurement were collected at the time
of endoscopy.
Total IgE was determined using the Phadia ImmunoCAPH solid
phase immunoassay (Pharmacia Diagnostics, Uppsala, Sweden).
Total serum IgE levels are given in kU/l. For some analyses,
patients were subgrouped into elevated- and normal-IgE-patients.
Expected normal ranges for this assay are 40 kU/l for age , one
year, 100 kU/l for the 2
nd year of life, 150 kU/l for the 3
rd year of
life, 190 kU/l for the 4
th and 5
th years of life, 150 kU/l for the 6
th
year of life, 120 kU/l for the 7
th to the 16
th year of life, and
100 kU/l for patients older than 16 years.
Statistical Analysis
Statistical analyses were carried out with SPSS software
(Version 17.0 SPSS Inc., Chicago, IL, USA). Differences in tissue
mRNA levels between groups were tested for statistical significance
with two-sided Kruskal-Wallis-H- test and two-sided Mann-
Whitney U-test with Bonferroni-Holm correction. Correlations
of data with serum IgE were determined using Spearman rank
correlation test. For certain analyses, total serum IgE values were
transformed into z-units to adjust for age dependent normal values
as published by Kjellman et al. [33]. P-values ,0.05 were
considered statistically significant.
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